IGM Biosciences Inc
Company Overview
IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies for the treatment of cancer patients. The company is developing a proprietary IgM antibody technology platform designed to overcome the manufacturing and protein engineering hurdles that have historically hindered the use of IgM antibodies for therapeutic applications.
The company's lead product candidate is IGM-2323, a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins, which is in Phase 1 clinical trials for the treatment of B cell lymphomas. The company is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of solid and hematologic malignancies.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $1.25m | $52.61m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate IGM Biosciences Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.